Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.

[1]  M. Schnitzler,et al.  The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age , 2021, Transplantation direct.

[2]  Jonathan A. Seaman,et al.  Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience. , 2020, Transplantation proceedings.

[3]  A. Mehta,et al.  Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five‐year follow‐up , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  G. Martínez-Mier,et al.  Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial. , 2020, Transplantation proceedings.

[5]  R. Pararajasingam,et al.  Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis , 2020, International Urology and Nephrology.

[6]  C. Jung,et al.  Effectiveness of Thymoglobulin Induction Therapy in Kidney Transplant From Deceased Donor With Mild to Moderate Acute Kidney Injury. , 2019, Transplantation proceedings.

[7]  O. Manuel,et al.  Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs. , 2019, The Journal of infectious diseases.

[8]  T. M. Moore Simas,et al.  Incidence of Venous Thromboembolism After Different Modes of Gynecologic Surgery. , 2018, Obstetrics and gynecology.

[9]  J. Lee,et al.  Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis. , 2018, Transplantation proceedings.

[10]  A. Teixeira-Pinto,et al.  Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients , 2017, Transplantation.

[11]  D. Abramowicz,et al.  Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti‐IL2 Receptor Monoclonal Antibodies? , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  J. Goss,et al.  Profiling risk for acute rejection in kidney transplantation: recipient age is a robust risk factor , 2017, Journal of Nephrology.

[13]  C. Kang,et al.  Prognostic Significance of 1-Year Serum Albumin Levels Within the Normal Range After Kidney Transplantation. , 2015, Artificial organs.

[14]  Bruce Kaplan,et al.  Survival benefit of solid-organ transplant in the United States. , 2015, JAMA surgery.

[15]  Gang Huang,et al.  Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. , 2013, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[16]  D. Brennan,et al.  Selection of induction therapy in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  C. Sommerer,et al.  Current pharmacotherapeutical options for the prevention of kidney transplant rejection , 2013, Expert opinion on pharmacotherapy.

[18]  G. Oniscu,et al.  Does national sharing of kidneys donated after cardiac death lead to poorer outcomes? , 2013, Transplantation proceedings.

[19]  G. Keating,et al.  Rabbit Antithymocyte Globulin (Thymoglobulin®) , 2009, Drugs.

[20]  Spencer T. Martin,et al.  Induction immunosuppressive therapies in renal transplantation. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[21]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[22]  Cees van Kooten,et al.  Chronic renal allograft rejection: pathophysiologic considerations. , 2005, Kidney international.

[23]  A. Sancho Calabuig,et al.  Acute rejection and late renal transplant failure: risk factors and prognosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  P I Terasaki,et al.  Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. , 2000, The New England journal of medicine.